Top Markets
Coin of the day
Fusion Antibodies plc Fusion Antibodies plc

Fusion Antibodies plc

FAB
株式のランク #20442
Fusion Antibodies plc, a contract research organization, engages in the... Fusion Antibodies plc, a contract research organization, engages in the research, development, and manufacture of recombinant proteins and antibodies primarily for cancer and infectious diseases in the United Kingdom, the rest of Europe, North America, and internationally. It offers monoclonal antibody discovery and development, antibody sequencing, antibody engineering, antibody humanization and rational affinity maturation platform, recombinant protein expression, and stable cell line development and cGMP scale up services. The company serves pharmaceutical, biotech, and diagnostic companies. It has a collaboration partnership with Celonic AG. Fusion Antibodies plc was incorporated in 2000 and is headquartered in Belfast, the United Kingdom.
株価
$0.16328419
時価総額
$204.14K
変化(1日)
4.35%
変化(1年)
102.45%
GB
取引 Fusion Antibodies plc (FAB)

カテゴリー

Fusion Antibodies plc(FAB)のP/S比率
March 2026 時点のP/S比率 TTM: 9.79
Fusion Antibodies plc の最新の財務報告および株価によると、現在のP/S比率(TTM)は 9.79 です。2024 年末時点でのP/S比率は 1.88 でした。
Fusion Antibodies plc の P/S 比率の履歴(2013 ~ 2026)
各年末時点のP/S比率
P/S比率 変化
2026 (TTM) 9.79 226.39%
2025 3.00 59.38%
2024 1.88 -45.47%
2023 3.45 6.43%
2022 3.24 -66.20%
2021 9.60 78.11%
2020 5.39 86.72%
2019 2.89 -54.34%
2018 6.32 -55.67%
2017 14.25 -22.61%
2016 18.42 -38.61%
2015 30.00 -20.48%
2014 37.73 -43.99%
2013 67.37 0.00%
同業他社のP/S比率
企業 P/S比率 P/S比率の差
3.55 -63.73%
DK
9.90 1.13%
US
5.40 -44.83%
US
6.14 -37.31%
BE
12.90 31.71%
NL